Operating leverage and CS strength support margins Growth visibility intact, but upside priced in ? Divi’s Laboratories (DIVI) delivered better-than-expected performance in 2Q with a 4%/10%/10% beat on revenue/EBITDA/PAT. While gross margin has been steady for the past eight quarters, DIVI has delivered improved EBITDA margin YoY as well as QoQ, led by better operating leverage. ?
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Choice
Contact Choice, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack